Literature DB >> 36237790

Emphysematous Pyelonephritis Involving Native Kidneys and a Transplanted Kidney.

Venu Chippa1, Swetha Chenna2, Rahul Gujarathi3.   

Abstract

Emphysematous pyelonephritis (EPN) is an acute severe necrotizing form of UTI, with air collection in the renal parenchyma, collecting system, and surrounding tissues. Most common causative organisms are Escherichia coli and Klebsiella. Here we present a 71-year-old Caucasian male with multiple medical problems who was transferred to our ER from a long-term acute care hospital (LTACH) for hematuria, UTI, and septic shock. He is a recipient of a deceased donor renal transplant and was receiving IV amphotericin B for recent cryptococcal meningitis. CT abdomen showed bilateral EPN, including the transplanted kidney. He received aggressive fluid resuscitation, vasopressors, and IV antibiotics and got admitted to the ICU. Unfortunately, his clinical course worsened and required ventilatory support, and his family opted for comfort care because of the high mortality rate. The emphasis of this case report is to investigate immunocompromised patients presenting with UTIs for EPN.
Copyright © 2022, Chippa et al.

Entities:  

Keywords:  emphysematous cystitis; emphysematous pyelonephritis; immunocompromised; septic shock; transplant kidney

Year:  2022        PMID: 36237790      PMCID: PMC9552574          DOI: 10.7759/cureus.29024

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  14 in total

1.  Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome.

Authors:  Ashok Kumar Sokhal; Manoj Kumar; Bimalesh Purkait; Ankur Jhanwar; Kawaljit Singh; Ankur Bansal; Satyanarayan Sankhwar
Journal:  Turk J Urol       Date:  2017-01-27

Review 2.  Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review.

Authors:  Bhaskar K Somani; Ghulam Nabi; Peter Thorpe; Jeff Hussey; Jonathan Cook; James N'Dow
Journal:  J Urol       Date:  2008-03-19       Impact factor: 7.450

3.  Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis.

Authors:  J J Huang; C C Tseng
Journal:  Arch Intern Med       Date:  2000-03-27

Review 4.  Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy.

Authors:  Patricia Brown; Moran Ki; Betsy Foxman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Emphysematous pyelonephritis.

Authors:  J Michaeli; P Mogle; S Perlberg; S Heiman; M Caine
Journal:  J Urol       Date:  1984-02       Impact factor: 7.450

6.  [Results of conservative management of emphysematous pyelonephritis].

Authors:  Ahmed Saadi; Haroun Ayed; Abderrazak Bouzouita; Mohamed Cherif; Walid Kerkeni; Selim Selmi; Riadh Ben Slama; Amine Derouiche; Mohamed Chebil
Journal:  Nephrol Ther       Date:  2016-10-24       Impact factor: 0.722

Review 7.  Renal allograft failure due to emphysematous pyelonephritis: successful non-operative management and proposed new classification scheme based on literature review.

Authors:  S M T Al-Geizawi; A C Farney; J Rogers; D Assimos; J A Requarth; W Doares; S Winfrey; R J Stratta
Journal:  Transpl Infect Dis       Date:  2010-09-02       Impact factor: 2.228

8.  Emphysematous pyelonephritis: a 15-year experience with 20 cases.

Authors:  A A Shokeir; M El-Azab; T Mohsen; T El-Diasty
Journal:  Urology       Date:  1997-03       Impact factor: 2.649

9.  Emphysematous pyelonephritis: clinical characteristics and prognostic factors.

Authors:  Yu-Chuan Lu; Bing-Juin Chiang; Yuan-Hung Pong; Chung-Hsin Chen; Yeong-Shiau Pu; Po-Ren Hsueh; Chao-Yuan Huang
Journal:  Int J Urol       Date:  2013-08-22       Impact factor: 3.369

10.  A case series of emphysematous pyelonephritis.

Authors:  Camelia Arsene; Abhijit Saste; Shankar Arul; Janee Mestrovich; Revark Kammo; Mohammed Elbashir; Gregory Berger
Journal:  Case Rep Med       Date:  2014-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.